Abstract Type I gastric carcinoids (TIGCs) are related to chronic atrophic gastritis and are characterized by hypergastrinemia and hyperplasia of enterochromaffin-like cells. TIGCs are the most frequently diagnosed of all gastric carcinoids, accounting for about 70-80 %. Endoscopically, TIGCs are present as small (\10 mm), polypoid lesions or, more frequently, as smooth, rounded submucosal lesions. Histologically, TIGCs arise in the deep mucosa, with some invading the submucosa. Most TIGCs are well-differentiated tumors, with metastasis being rare. Therefore, patients with TIGCs generally have an excellent prognosis. Among the currently available treatment options are total gastrectomy, partial resection, antrectomy, endoscopic resection, and endoscopic surveillance, although no consensus has been reached on their optimal management. Further studies are needed to develop better management options for patients with TIGC.
Introduction
Carcinoids arise from cells of the diffuse neuroendocrine system and are, therefore, also called neuroendocrine tumors [1] . The incidence of gastric carcinoids (GC) among all gastrointestinal carcinoids (GICs) has gradually increased [2] [3] [4] , making it important to understand the clinical features and management of GCs. GCs can be classified into three distinct subgroups, with Table 1 showing the clinical characteristics of these three types [5] [6] [7] [8] [9] [10] [11] .
Type I GCs (TIGCs) arise in patients with chronic atrophic gastritis (CAG), including autoimmune gastritis (AIG; i.e. type A gastritis) and Helicobacter pyloriassociated atrophic gastritis [12, 13] . TIGCs are associated with hypergastrinemia and hyperplasia of enterochromaffin-like (ECL) cells. TIGCs are often small (\10 mm), occurring as multiple tumors in individual patients, and are located in the gastric fundus or corpus. Most tumors are limited to the mucosa or submucosa. TIGCs are the most frequently diagnosed of all GCs, accounting for about 70-80 %. TIGCs tend to display a nearly benign behavior with a low risk for progression or metastasis.
Type II GCs are rare and account for 5-6 % of all GCs. They are associated with gastrin-producing neoplasms in patients with multiple endocrine neoplasia/Zollinger-Ellison syndrome. Similar to TIGCs, type II GCs are small and multiple, associated with hypergastrinemia and hyperplasia of ECL cells, and considered benign.
In contrast, type III GCs are sporadic carcinoids without specific background factors, therefore, occurring under normogastrinemic conditions. Type III GCs are often single and large tumors, accounting for 10-15 % of all GCs. These tumors behave more aggressively, with higher rates of metastasis and regional lymph node involvement.
In Japan, TIGCs constitute 87.1 % of all GCs [14] . This review focuses on the epidemiology, pathogenesis, diagnosis, and management of TIGCs.
Epidemiology
GCs are rare tumors, although their incident rates have gradually increased. For example, over a 35-year period, the incidence of GC in the United States has increased nearly tenfold [2] , while the incidence of GC in the UK has increased 23-fold in men and 47-fold in women [3] . As of 1999, the percentage of GCs among all gastric malignancies in the United States increased from 0.3 to 1.77 % over 50 years, and the percentage of GCs among all GICs increased from 2.4 to 8.7 % over 30 years [4] . More recent reports have revealed that the ratio of GCs to all GICs has increased further, at rates of 12 % in the UK [3] , 23 % in Austria [15] , 14.6 % in Korea [16] , 11.9 % in the United States [17] , and 15.1 % in Japan [14] . Although these increases in the incidence of GCs may be due in part to a true increase in the incidence, they may also be due to improvements in diagnostic technology, including endoscopy, and an increased awareness of GCs.
Since no specific symptoms are associated with TIGC, most TIGCs are detected incidentally during endoscopy. TIGCs are more prevalent in women than in men [9, 12] , owing to the greater incidence of AIG in women [18] . In Japan, however, TIGC is more common in men than in women [19] , perhaps owing to the lower rates of cooccurrence of TIGC and AIG.
Pathophysiology
On ingestion of food, antral G cells in the stomach secrete gastrin, which binds to cholecystokinin-2 (CCK-2) receptors located on the membranes of ECL cells, leading to histamine release. Histamine binds to H2 receptors on gastric parietal cells to produce hydrochloric acid. In the AIG, anti-parietal cell antibodies act on gastric parietal cells, leading to achlorhydria, which induces G cell hyperplasia and their secretion of additional gastrin, resulting in hypergastrinemia.
Gastrin stimulates gastric epithelial cell proliferation and acts as a trophic factor for ECL cells, leading to ECL cell hyperplasia. Therefore, in some patients, hypergastrinemia can lead to TIGC development. Since only some patients with AIG develop TIGC, other cofactors, such as Reg [20] , mcl-1 [21] , and MEN-1 gene mutation [22] , may play a role in the development of TIGC.
In H. pylori associated gastritis, H. pylori induces hypergastrinemia [23, 24] . H. pylori infection is a risk factor for the development of gastric mucosal atrophy, resulting in low acid output [25] . Antibodies against H. pylori may act as autoantibodies to parietal cells [26] [27] [28] . Additionally, hypergastrinemia related to H. pylori infection would be due to up-regulation of tumor necrosis factor-a and interleukin-b and down-regulation of somatostatin [29] . Furthermore, H. pylori lipopolysaccharide stimulates DNA synthesis in ECL cells, suggesting that it may act on ECL cell hyperplasia [30] . H. pylori infection may, therefore, be a risk factor for TIGC by inducing hypergastrinemia [13, 31] . In either AIG or H. pylori-associated gastritis, under the condition of CAG, a lack of gastric acid production results in hyperplasia of G cells and hypergastrinemia, leading to TIGC development.
Diagnosis
Most patients with TIGCs do not complain of flushing or any other symptoms related to carcinoid syndrome [32, 33] . However, patients with TIGC have nonspecific symptoms, such as nausea, abdominal pain, and/or dyspepsia [34] , or pernicious anemia complicated by AIG. Therefore, TIGCs are detected incidentally during screening by esophagogastroduodenal endoscopy. Endoscopically, TIGC is present as polypoid lesions or, more frequently, as smooth and rounded submucosal lesions [35] . TIGCs are often found in the gastric corpus or fundus, are small in size (\10 mm), and multiple. Narrow band imaging and high resolution magnification endoscopy may be helpful for the endoscopic diagnosis of TIGC [36] .
Histologically, TIGCs are composed of small uniform cells in nests and infiltrating strands, or with an anastomosing ribbon-like, tubular, or acinar pattern. These tumors arise in the deep mucosa, in some cases invading the submucosa. Moreover, these tumors are covered by normal mucosa, requiring deeper biopsy to remove specimens adequate for diagnosis. Sampling biopsy should not include only the TIGC lesion, but also both the antrum and the corpus/fundus to assess for the presence of atrophic gastritis and precursor lesions of TIGCs [37] .
Hyperplastic and dysplastic ECL cells are considered precursors of ECL cell carcinoids [38] and are often detected in biopsy specimens from non-tumor mucosa adjacent to tumors. The 2010 World Health Organization (WHO) classification system has defined ECL cell hyperplasia as diffuse, linear, micronodular, or adenomatoid hyperplasia, whereas ECL cell dysplasia is characterized by enlarged or fused micronodules, microinvasion, or newly formed stroma [1, 39] . Nodules that increase in size to [0.5 mm or invade the submucosa are classified as microcarcinoids (\0.5 cm) or plain carcinoids (C0.5 cm) [1] .
GCs are classified histologically by grade and differentiation. The 2010 WHO classification system grades GCs by counting mitoses and by the Ki67 index: G1,\2 mitoses per 10 high power fields (HPF) (=2 mm 2 ) and/or a Ki67 index B2 %; G2, 2-20 mitoses per 10 HPF and/or a Ki67 index of 2-20 %; or G3, [20 mitoses per 10 HPF and/or a Ki67 index [20 % [40] . Most TIGCs are classified as G1 tumors.
Endoscopic ultrasonography is useful for assessing the depth of gastric wall invasion of tumors[1 cm in size [41] . CT or MRI scan can provide useful information in patients with metastatic disease. The role of fluorodeoxyglucose positron emission tomography in assessing TIGCs is unclear [42] . Octreoscan can be used to assess metastases and somatostatin receptor status if treatment with somatostatin receptor antagonist is being considered [43] . However, Octreoscan is generally unavailable in Japan.
Prognosis
Since most TIGCs are G1 tumors and are limited to the mucosa or submucosa, patients with TIGCs generally have an excellent prognosis. Endoscopic resection of localized T1 lesions can achieve a close to 100 % survival rate [44] . A recent report of a large series of patients with TIGC found that the rate of lymph node metastases was 5.3 % and the rate of tumor-associated death was 1.07 % [45] . Tumor size and depth predict lymph node metastasis [46] . Although most patients with TIGCs classified as G1 had an excellent prognosis, those with TIGCs classified as G2 and G3 had poorer or very severe prognosis, respectively [45] . Metastatic TIGC is related to be a tumor size C1 cm, an elevated Ki-67 index and high serum gastrin levels [47] . Therefore, assessment of tumor size, depth, and histological stage may be predictive of patient prognosis.
Management
The clinical management and treatment of patients with TIGC depend on tumor size and the presence of risk factors, including muscle wall infiltration, increased proliferation, and/or metastasis. Hitherto, endoscopic resection has been recommended for patients with a few (\3-5 lesions) small (\1 cm) TIGCs, whereas antrectomy or local resection is recommended for patients with many ([3-5 lesions) or large ([1 cm) TIGCs [48] . However, resent studies revealing the generally indolent nature of TIGCs led to a shift in management and treatment. Patients with small tumors and lacking risk factors have been managed by simple observation, without endoscopic or surgical resection [12, 19, 32, 37, 49, 50] . In contrast, the ENETS guidelines have recommended that all TIGCs should be removed whenever possible, although tumor development has not been found to be less favorable in patients with tumors \10 mm left in place [37] . NCCN guidelines [50] have recommended that patients with locoregional TIGC B 20 mm in size undergo (a) endoscopic surveillance every 6-12 months, and (b) endoscopic resection, if feasible, with biopsy of the tumor and adjacent mucosa.
The treatment of TIGCs 10-20 mm in size is unclear. In the WHO classification, GCs 1 cm in size is the cut-off defining T1 and T2 tumors. ENETS guidelines have suggested endoscopic removal of TIGCs larger than 10 mm in size without invasion of the muscularis propria and lymph nodes, and surgical resection of tumors with involvement beyond the submucosa or lymph nodes or with distant disease [37] . However, NCCN guidelines have recommended either endoscopic resection or observation of local TIGCs 10-20 mm in diameter.
ENETS guidelines recommend endoscopic mucosal resection (EMR) of TIGCs that have not invaded the muscularis propria. However, TIGCs frequently invade the submucosa [19] , making it difficult to remove TIGCs completely, even small ones, by snare polypectomy or conventional EMR. In contrast, endoscopic submucosal dissection (ESD) is a feasible technique for the removal of tumors present in the submucosal layer, such as TIGCs. Recent reports have revealed that the complete resection rate of GC tumors was higher with ESD than with EMR [51, 52] .
Surgical resection is generally recommended for TIGCs larger than 20 mm in diameter or those that extend deeper than the submucosa [37, 50] . Moreover, the latest ENETS guidelines endorsed the use of surgery in patients with lymph node or distant disease spread, and in those with poorly differentiated neoplasms [37] . Surgery should include local resection and antrectomy to reduce gastrin levels. However, antrectomy may not be effective in preventing recurrence and/or metastasis [53] .
Patients with locoregionally unresectable and/or metastatic TIGCs should be treated with somatostatin analogs (SSAs) and/or undergo complete resection of the primary tumor and metastases. Treatment with SSAs has been shown effective in reducing the number and size of TIGCs [54] [55] [56] . SSAs act on G cells to inhibit gastrin secretion and have a role in reducing ECL cell hyperplasia. However, use of SSAs cannot be recommended, because their effects are short-term, with tumor progression occurring after the completion of SSA treatment [57] . Recently, natazepide (YF476), a peripheral gastrin (CCK-B) receptor antagonist, has been reported to inhibit acid secretion and ECL cell proliferation and to reduce the size and number of TIGCs [58] . Large, long-term, follow-up studies are needed to determine the efficacy of this CCK-B receptor antagonist in the treatment of TIGCs.
After treatment, the ENETS guidelines recommend endoscopic surveillance every 12 months in patients with tumor recurrence, and every 24 months in patients without tumor recurrence [37] . NCCN guidelines have recommended that patients with small (B20 mm) TIGCs who did not require endoscopic resection or treatment should be evaluated by patient history and physical examination every 6-12 months [50] . Moreover, in the absence of tumor recurrence or progression, follow-up endoscopies should be performed every 6-12 months for the first 3 years and annually thereafter [50] . However, an optimal follow-up schedule has not yet been established as a clinical standard.
Conclusion
TIGCs are related to CAG with hypergastrinemia and hyperplasia of ECL cells. The incidence of GCs has significantly increased, with the great majority of GCs being TIGCs. TIGCs are present as small (\10 mm) and multiple lesions endoscopically, and are generally limited to the mucosa or submucosa. TIGCs tend to display a nearly benign behavior with a low risk for progression or metastasis. Several treatment options are currently available for TIGCs, but their optimal management has not been established. Further studies on TIGCs are needed to develop new promising management for patients with these tumors. Informed Consent: This study does not apply to giving Informed Consent because the present manuscript is a review article.
